Trials / Completed
CompletedNCT00384280
Study to Determine the Impact of Multiple Doses of Rifampin on Single-dose Pharmacokinetics of HCV-796
An Open Label, 2-period, Sequential Study to Determine the Impact of Multiple Doses of Rifampin on Single-dose Pharmacokinetics of HCV-796
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
An open label, 2-period, sequential study to determine the impact of multiple doses of rifampin on single-dose pharmacokinetics of HCV-796
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rifampin |
Timeline
- Start date
- 2006-09-01
- Primary completion
- 2006-11-01
- Completion
- 2006-11-01
- First posted
- 2006-10-06
- Last updated
- 2009-08-12
Source: ClinicalTrials.gov record NCT00384280. Inclusion in this directory is not an endorsement.